Coeurative, Inc

Coeurative pioneers novel coronary vasodilators to restore heart health through smarter science and compassionate innovation.

[Coeurative, Inc @CoeurativeInc]

After 3+ decades treating patients with debilitating chest pain, Dr. John Schmedtje kept seeing the same problem: even with today’s best therapies, too many people with coronary artery disease and refractory angina still couldn’t live the lives they wanted.

#RefractoryAngina

[Coeurative, Inc @CoeurativeInc]

1 in 5 angina patients experience debilitating attacks monthly, even on modern medical therapy. 

These are not patients who have been ignored; they've tried everything available.

The unmet need is profound.
#Angina #CardiovascularHealth #UnmetMedicalNeed

[Coeurative, Inc @CoeurativeInc]

Annual mortality rates for refractory angina patients reach up to 17%. 

Current standard-of-care options fail to address this devastating risk, creating an urgent imperative for first-in-class therapies.

#RefractoryAngina #CardiovascularDisease
#UnmetMedicalNeed #FirstInClass

[Coeurative, Inc @CoeurativeInc]

We had a great JPM and look forward to continuing to connect with others and tell the Coeurative story.

Visit our website below to learn more!
https://t.co/gBQEcUHCLC

[Coeurative, Inc @CoeurativeInc]

In the United States, an estimated 75,000 new refractory angina cases are diagnosed every year.

Together, this population represents a substantial and expanding group in urgent need of new therapeutic approaches.

#RefractoryAngina #UnmetMedicalNeed #Cardiology #Biotech

[Coeurative, Inc @CoeurativeInc]

$15B+ global market opportunity by 2029. 

Over 10 million Americans live with angina pectoris, yet 21% still suffer monthly attacks despite current therapies.

The market is calling for innovation.

#CardiovascularHealth #Angina #UnmetMedicalNeed #HealthcareInnovation

[Coeurative, Inc @CoeurativeInc]

Coeurative, Inc. aims to redefine the care of patients with INOCA by addressing causes of anginal chest pain with precision, compassion, & science.

We predict that our groundbreaking therapy, CR-0305, will offer hope when existing therapeutics fall short.

#INOCA #PatientFirst

[Coeurative, Inc @CoeurativeInc]

At COEURative, we believe patients with refractory angina deserve more than symptom management—they deserve pharmaceutical innovation.

Watch as our founder, John Schmedtje, discusses how we plan to develop a revolutionary therapy for patients.

#RefractoryAngina #PatientFirst